Rising Public Interest in Weight Loss Medications and Growing Awareness of Their Aesthetic Sequelae: An Infodemiologic Google Trends Analysis and Clinical Diagnostic Patterning
Journal of Cosmetic Dermatology · 2026-01 · 25 (1)
DOI: 10.1111/jocd.70670 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 12.01.2026. Verfasst von Alec D McCarthy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Global Medical Affairs, Merz Aesthetics, Raleigh, North Carolina, USA. Hauptthemen laut MEDLINE: Esthetics, Glucagon-Like Peptide-1 Receptor Agonists, Anti-Obesity Agents, Search Engine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merz Aesthetics.
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained rapid popularity for both medical and consumer‐directed weight loss. This growth has been accompanied by increased public discussion regarding facial aesthetic changes, commonly referred to as “Ozempic face,” characterized by volume depletion and cutaneous laxity.
Objective
To quantify temporal patterns of public search interest in a widely known GLP‐1 RA and evaluate corresponding awareness of its cosmetic facial sequelae using infodemiologic methods.
Methods
Google Trends data for “Ozempic” and related frequently co‐searched queries were analyzed from November 2021 to December 2024. Trends in relative search volume (RSV) were examined, with particular focus on terms associated with facial aesthetics, including “Ozempic face” and “plastic surgeons Ozempic face.” Results RSV for “Ozempic” showed a steady upward trajectory over the study period. Queries related to facial aesthetic consequences exhibited substantial proportional increases. Notably, “Ozempic face” demonstrated a 4600% rise in RSV, and searches for “plastic surgeons Ozempic face” similarly grew markedly.
Conclusions
Public interest in GLP‐1 RAs is strongly associated with rising awareness and concern about their facial aesthetic effects. These trends suggest that aesthetic practitioners should expect more patient inquiries regarding GLP‐1–related facial changes and should proactively integrate counseling and corrective treatment options into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Medical Affairs, Merz Aesthetics, Raleigh, North Carolina, USA.
- K. Kay Durairaj, M.D., A Medical Corp, Pasadena, California, USA.
- Derma Skin Institute, Guelph, Ontario, Canada.
- McMaster University, Hamilton, Ontario, Canada.
- Innovative Dermatology, Plano, Texas, USA.
- Ocean Drive Plastic Surgery, Dermatology, and MedSpa, Vero Beach, Florida, USA.
ORCID-Profile: Alec D McCarthy, Kay Durairaj, Jacob Linneman-Heath, Mara Dacso, Alan Durkin
Förderung
- Merz Aesthetics
Zitieren
APA
McCarthy, A. D., Durairaj, K., Linneman-Heath, J., Sajic, D., Dacso, M., & Durkin, A. (2026). Rising Public Interest in Weight Loss Medications and Growing Awareness of Their Aesthetic Sequelae: An Infodemiologic Google Trends Analysis and Clinical Diagnostic Patterning. Journal of Cosmetic Dermatology, 25(1). https://doi.org/10.1111/jocd.70670
Vancouver
McCarthy AD, Durairaj K, Linneman-Heath J, Sajic D, Dacso M, Durkin A. Rising Public Interest in Weight Loss Medications and Growing Awareness of Their Aesthetic Sequelae: An Infodemiologic Google Trends Analysis and Clinical Diagnostic Patterning. Journal of Cosmetic Dermatology. 2026;25(1). doi:10.1111/jocd.70670
BibTeX
@article{McCarthy2026,
author = {McCarthy, Alec D and Durairaj, Kay and Linneman-Heath, Jacob and Sajic, Dusan and Dacso, Mara and Durkin, Alan},
title = {Rising Public Interest in Weight Loss Medications and Growing Awareness of Their Aesthetic Sequelae: An Infodemiologic Google Trends Analysis and Clinical Diagnostic Patterning},
journal = {Journal of Cosmetic Dermatology},
year = {2026},
volume = {25},
number = {1},
doi = {10.1111/jocd.70670}
}
EUVIMED